<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835718</url>
  </required_header>
  <id_info>
    <org_study_id>2009_533</org_study_id>
    <secondary_id>MK0594-020</secondary_id>
    <nct_id>NCT00835718</nct_id>
  </id_info>
  <brief_title>A Study of MK0594 in Patients With Alcohol Dependence</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK0594 in Patients With Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study in patients with alcohol dependence to see if MK0594 is safe and effective in
      maintaining absence of heavy drinking over a 12-week treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no heavy alcohol drinking and safety as measured by adverse experiences, laboratory safety test, vital signs, ECG, and physical examination</measure>
    <time_frame>week 3 and 12 adrer starting study medication for efficacy and over 12 weeks and 52 weeks for safety</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>no alcohol drinking</measure>
    <time_frame>week 3 to 12 after starting study medication and over 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Stage I, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0594 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I, Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II, Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0594 1 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II, Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0594 1 mg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II, Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0594 5 mg/day</intervention_name>
    <description>MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.</description>
    <arm_group_label>Stage I, Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0594 1 mg/day</intervention_name>
    <description>MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.</description>
    <arm_group_label>Stage II, Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0594 1 mg/week</intervention_name>
    <description>MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.</description>
    <arm_group_label>Stage II, Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo to MK0594</intervention_name>
    <description>Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.</description>
    <arm_group_label>Stage I, Arm 2</arm_group_label>
    <arm_group_label>Stage II, Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has DSM-IV-TR diagnosis of alcohol dependence and alcohol addiction

          -  Patient has two heavy drinking days in the last 30 days

          -  Patient has 3 days of abstinence from alcohol right before taking study medication

          -  Patient has lived in the same residence for the last 2 months

        Exclusion Criteria:

          -  If female, patient is pregnant or breastfeeding

          -  Patient anticipated inpatient alcohol treatment

          -  Patient has a history of suicide attempt in the last year

          -  Patient has schizophrenia or bipolar disorder

          -  Patient has a history of multiple or serious allergies

          -  Patient has participated in a clinical trial in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <last_update_submitted>March 26, 2010</last_update_submitted>
  <last_update_submitted_qc>March 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck Sharp &amp; Dohme Corp</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

